Source:http://linkedlifedata.com/resource/pubmed/id/20067764
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2010-2-15
|
pubmed:abstractText |
To develop a novel dendritic cell (DC)-based vaccine for inducing antigen-specific CD8+ T cell responses by cross-presentation, we tested a novel antigen delivery system that introduces soluble antigens into the cytosol of cells by an endocytosis-mediated mechanism which avoids damaging the plasma membrane ("Endo-Porter"). Proteins released from endosomes into the cytoplasm are degraded by the proteasome, and fragmented antigenic peptides are presented to the classical cytosolic MHC class I pathway. DCs pulsed with OVA protein in the presence of Endo-Porter efficiently stimulate OVA peptide-specific CD8+ T (OT-I) cells. Although this agent diverts some of the endocytosed antigens away from the classical MHC class II-restricted presentation pathway to the class I pathway, the activation of CD4+ T cells was found not to be hampered by Endo-Porter-mediated antigen delivery. On the contrary, it was rather augmented, probably due to the increased uptake of antigen. Because specific CD4+ T cell help is required to license DCs for cross-priming, Endo-Porter-mediated antigen delivery is a promising approach for developing more efficient cancer vaccines targeting both CD4+ and CD8+ T cells.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical |
http://linkedlifedata.com/resource/pubmed/chemical/Antigens,
http://linkedlifedata.com/resource/pubmed/chemical/Cancer Vaccines,
http://linkedlifedata.com/resource/pubmed/chemical/Endo-Porter,
http://linkedlifedata.com/resource/pubmed/chemical/Histocompatibility Antigens Class I,
http://linkedlifedata.com/resource/pubmed/chemical/Peptides
|
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1090-2104
|
pubmed:author |
pubmed-author:FujiiShin-IchiroS,
pubmed-author:FutamiJunichiroJ,
pubmed-author:HosoiAkihiroA,
pubmed-author:IkeuchiNobuhitoN,
pubmed-author:KakimiKazuhiroK,
pubmed-author:KurachiMakotoM,
pubmed-author:MatsushimaKojiK,
pubmed-author:MoriyasuFuminoriF,
pubmed-author:NojiShuichiS,
pubmed-author:UehaSatoshiS,
pubmed-author:YamadaHidenoriH
|
pubmed:copyrightInfo |
2010 Elsevier Inc. All rights reserved.
|
pubmed:issnType |
Electronic
|
pubmed:day |
5
|
pubmed:volume |
392
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
217-22
|
pubmed:meshHeading |
pubmed-meshheading:20067764-Animals,
pubmed-meshheading:20067764-Antigens,
pubmed-meshheading:20067764-CD4-Positive T-Lymphocytes,
pubmed-meshheading:20067764-CD8-Positive T-Lymphocytes,
pubmed-meshheading:20067764-Cancer Vaccines,
pubmed-meshheading:20067764-Cross-Priming,
pubmed-meshheading:20067764-Cytosol,
pubmed-meshheading:20067764-Dendritic Cells,
pubmed-meshheading:20067764-Endocytosis,
pubmed-meshheading:20067764-Histocompatibility Antigens Class I,
pubmed-meshheading:20067764-Lymphocyte Activation,
pubmed-meshheading:20067764-Mice,
pubmed-meshheading:20067764-Mice, Inbred C57BL,
pubmed-meshheading:20067764-Peptides
|
pubmed:year |
2010
|
pubmed:articleTitle |
Efficient cross-presentation of soluble exogenous antigens introduced into dendritic cells using a weak-based amphiphilic peptide.
|
pubmed:affiliation |
Department of Gastroenterology and Hepatology, Tokyo Medical University, Tokyo, Japan.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|